Celltrion Inc. has received European Medicines Agency (EMA) approval for the world’s first subcutaneous (SC) biosimilar version of infliximab, Remsima SC, giving the South Korean company another foothold to evolve into a truly global enterprise, as it laid out its commercial plans and strategy for the roll-out in Europe.
The formal regulatory nod came after the company received a positive opinion in the EU in mid-September for its approval...